➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Moodys
Medtronic
Express Scripts
AstraZeneca

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Imiglucerase - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for imiglucerase

Identify potential brand extensions & biosimilar entrants

SponsorPhase
SanofiPhase 3
Shaare Zedek Medical CenterN/A
PfizerN/A

See all imiglucerase clinical trials

Recent Litigation for imiglucerase

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
MiMedx Group, Inc. v. Tissue Transplant Technology, Ltd.2014-05-16

See all imiglucerase litigation

Company Disclosures: US Patents for imiglucerase

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CEREZYME imiglucerase INJECTABLE;INJECTION 020367 001 1995-04-07   Start Trial Genzyme Corporation (Cambridge, MA) 2010-08-17 RX company
Genzyme CEREZYME imiglucerase INJECTABLE;INJECTION 020367 001 1995-04-07   Start Trial Genzyme Corporation (Cambridge, MA) 2013-08-27 RX company
Genzyme CEREZYME imiglucerase INJECTABLE;INJECTION 020367 002 1995-04-07   Start Trial Genzyme Corporation (Cambridge, MA) 2010-08-17 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for imiglucerase

These patents were identified by searching patent claims

Supplementary Protection Certificates for imiglucerase

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2015 Austria   Start Trial PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
2015 00017 Denmark   Start Trial PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
678 Luxembourg   Start Trial PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.